title: The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes.
abstract: BACKGROUND
  The GH-2000 team proposed a method based on IGF1 and type III pro-collagen (P-III-P) to detect exogenously administered GH. As previous studies involved predominantly white European athletes, it is important to assess whether the response of these markers to recombinant human GH (rhGH) differs with ethnicity.
  
  
  OBJECTIVE
  To examine the response of serum IGF1 and P-III-P and GH-2000 score to rhGH in non-Caucasian amateur athletes.
  
  
  METHODS
  Double-blind placebo-controlled rhGH administration study.
  
  
  METHODS
  Wellcome Trust Clinical Research Facility, Southampton General Hospital.
  
  
  METHODS
  The study included 31 male and 14 female amateur athletes of different ethnicities. Intervention The subjects were assigned to treatment with placebo or 0.1 IU/kg per day (low dose) or 0.2 IU/kg per day (high dose) rhGH for 28 days. Blood was collected weekly during treatment and on days 35, 42 and 84 during the washout period. Serum IGF1 and P-III-P were measured, and GH-2000 score was calculated.
  
  
  RESULTS
  IGF1, P-III-P and GH-2000 score rose in response to both low- and high-dose GH in both men and women. When compared with the Caucasian volunteers of the previous GH-2000 study, mean baseline and placebo-treated P-III-P and GH-2000 score were lower in GH-2004 men and women. Post-GH, however, peak IGF1 or P-III-P did not differ between studies but the peak GH-2000 score was lower in GH-2004 men. There was no difference between studies in the maximal change in IGF1, P-III-P and GH-2000 score in response to GH in either gender.
  
  
  CONCLUSIONS
  These data do not support a significant ethnic effect on the peak or maximal response to rhGH.
authors.affiliation: Endocrinology and Metabolism, Developmental Origins of Health and Disease Division, The Institute of Developmental Sciences IDS Building, MP887, Southampton General Hospital, University of Southampton School of Medicine, Tremona Road, Southampton SO16 6YD, UK. .i.g.holt@southampton.ac.uk
authors.forename: Richard I G
authors.initials: RI
authors.lastname: Holt
authors.forename: Ioulietta
authors.initials: I
authors.lastname: Erotokritou-Mulligan
authors.forename: Cathy
authors.initials: C
authors.lastname: McHugh
authors.forename: E Eryl
authors.initials: EE
authors.lastname: Bassett
authors.forename: Christiaan
authors.initials: C
authors.lastname: Bartlett
authors.forename: Adam
authors.initials: A
authors.lastname: Fityan
authors.forename: Jenny L
authors.initials: JL
authors.lastname: Bacon
authors.forename: David A
authors.initials: DA
authors.lastname: Cowan
authors.forename: Peter H
authors.initials: PH
authors.lastname: Sönksen
mesh_terms: D000293:Adolescent; D000328:Adult; D056352:Athletes; D024061:Collagen Type III / Q000097:blood*; D004300:Doping in Sports / Q000208:ethnology; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D015990:Placebo Effect; D044469:Racial Groups; D055815:Young Adult
chemical_list: D024061:Collagen Type III; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone